MaxCyte Inc
LSE:MXCT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (29.2), the stock would be worth GBX87.36 (11 554% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.3 | GBX0.75 |
0%
|
| Industry Average | 29.2 | GBX87.36 |
+11 554%
|
| Country Average | 19.6 | GBX58.74 |
+7 736%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
GBX-26.8m
|
/ |
Jan 2026
$-44.5m
|
= |
|
|
GBX-26.8m
|
/ |
Dec 2026
$-37.2m
|
= |
|
|
GBX-26.8m
|
/ |
Dec 2027
$-29.2m
|
= |
|
|
GBX-26.8m
|
/ |
Dec 2028
$-7m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
M
|
MaxCyte Inc
LSE:MXCT
|
91.8m GBP | 0.3 | -2.1 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 2 360.7 | 4 278.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
197.9B USD | 27.2 | 29.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
138.2B USD | 27.7 | 37.4 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 39.4 | 46.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
36.1B CHF | 26.9 | -126 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
297.7B CNY | 15.9 | 15.3 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
34.2B USD | 23.1 | 26.7 | |
| US |
|
Waters Corp
NYSE:WAT
|
32.9B USD | 41.7 | 51.4 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
30B USD | 18.3 | 22.2 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27B USD | 25.4 | 30.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
MaxCyte Inc
Glance View
MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
